What Is The Non Invasive Prenatal Test? Explained

A simple blood draw from a pregnant person’s arm can now reveal information about the developing fetus. That is the basic idea behind the non invasive prenatal test, often shortened to NIPT. It is a screening test, not a diagnosis, and understanding that distinction matters before you decide whether to have it.

The non invasive prenatal test is a blood test offered during pregnancy that analyzes small fragments of DNA circulating in the pregnant person’s bloodstream. These fragments, called cell-free DNA, come from both the pregnant person and the placenta. By examining the placental DNA, the test estimates the chance that a fetus has certain chromosomal conditions, most commonly trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Because it requires only a blood sample, it carries no risk of miscarriage, unlike invasive tests such as amniocentesis or chorionic villus sampling.

What Is The Non Invasive Prenatal Test Actually Measuring?

The test measures cell-free DNA, which is short fragments of genetic material that enter the bloodstream when cells break down. During pregnancy, a portion of this DNA comes from the placenta. The placenta and the fetus typically share the same genetic makeup, so analyzing placental DNA gives information about the fetus.

Laboratories count the relative amount of DNA from each chromosome. If there is more DNA from chromosome 21 than expected, for example, that suggests the fetus may have an extra copy of that chromosome. This approach is sometimes called a counting method. It does not read the full genetic code. It looks for imbalances in chromosome amounts.

This is why NIPT is described as a screening test. It estimates probability. It does not provide a definitive answer. A high-risk result means further testing is needed to confirm whether a chromosomal condition is actually present.

When Can You Have NIPT Done?

NIPT is typically performed after 10 weeks of pregnancy. Before that point, there may not be enough fetal DNA in the pregnant person’s blood to produce a reliable result.

The test can be done at any point after 10 weeks, though some clinicians prefer to wait until 12 weeks or later to reduce the chance of an inconclusive result. The exact timing recommendation depends on the specific laboratory and the clinical situation.

NIPT is not the same as other prenatal screening tests. First-trimester combined screening, which uses ultrasound and blood markers, is usually offered between 11 and 14 weeks. Second-trimester maternal serum screening, sometimes called the quad screen, is done between 15 and 22 weeks. These tests measure proteins and hormones rather than DNA. They screen for a broader range of conditions, including neural tube defects, which NIPT does not reliably detect.

What Conditions Can NIPT Screen For?

The core conditions NIPT screens for are trisomy 21, trisomy 18, and trisomy 13. These are the three most common autosomal trisomies that can survive to birth.

Trisomy 21, or Down syndrome, occurs when there is an extra copy of chromosome 21. It is the most common chromosomal condition in live births. Trisomy 18 and trisomy 13 are less common and typically associated with more severe health challenges.

Some NIPT panels also screen for sex chromosome conditions, such as Turner syndrome and Klinefelter syndrome. The accuracy for these conditions is generally lower than for trisomy 21. Some panels offer screening for certain microdeletions, which are small missing pieces of chromosomes. The evidence for microdeletion screening is weaker, and professional guidelines generally do not recommend it as a routine part of care.

NIPT does not screen for all genetic conditions. It does not detect neural tube defects like spina bifida. It does not detect single-gene disorders like cystic fibrosis or sickle cell disease unless a specialized panel is used. It is not a substitute for carrier screening, which tests the parents for gene mutations they might pass on.

How Accurate Is NIPT?

For trisomy 21, NIPT is highly accurate. Research consistently shows detection rates above 99% for trisomy 21 in high-risk populations, with low false positive rates. For trisomy 18 and trisomy 13, detection rates are somewhat lower but still high.

Accuracy depends on several factors. One is the fetal fraction, which is the percentage of cell-free DNA in the blood that comes from the placenta. If the fetal fraction is too low, the test may not produce a result. Fetal fraction tends to be lower in early pregnancy, in people with higher body mass index, and in certain other situations.

Another factor is the population being tested. A test with high sensitivity and specificity can still produce more false positives than true positives when the condition is rare. This is a basic principle of screening. It is why a positive NIPT result is not a diagnosis and why confirmatory testing is recommended.

NIPT can also produce results that reflect the placenta rather than the fetus. This is called confined placental mosaicism. In these cases, the placenta has an abnormal chromosome count while the fetus does not. This can lead to a high-risk NIPT result even when the fetus is unaffected.

What Happens If NIPT Shows a High-Risk Result?

A high-risk result means the test found an increased chance of a chromosomal condition. It does not mean the fetus definitely has that condition. Confirmatory testing is needed.

The standard confirmatory tests are amniocentesis and chorionic villus sampling, often called CVS. Amniocentesis involves removing a small amount of amniotic fluid, usually between 15 and 20 weeks. CVS involves taking a sample of placental tissue, usually between 10 and 13 weeks. Both are invasive and carry a small risk of miscarriage. The exact risk varies by provider and technique, but current estimates are generally lower than older figures sometimes cited.

Some people choose not to have confirmatory testing. That is a personal decision. A genetic counselor can help explain what a high-risk result means and what the options are.

If NIPT shows a low-risk result, it means the chance of the screened conditions is low. It does not guarantee the fetus has no chromosomal or genetic condition. NIPT does not screen for everything.

Who Should Consider NIPT?

Professional guidelines generally recommend that NIPT be offered to all pregnant people, regardless of age or risk level. This is a change from earlier recommendations, which focused on people at higher risk, such as those over 35.

NIPT is a screening test, so it is optional. Some people want the information. Others prefer not to have it. There is no right answer for everyone.

NIPT may be less informative in certain situations. These include pregnancies with twins or more, pregnancies achieved with an egg donor, and situations where the pregnant person has certain medical conditions or medications. In these cases, the test may not produce a result or may be less accurate.

Cost and insurance coverage vary. Some insurance plans cover NIPT for people at higher risk. Coverage for average-risk pregnancies has expanded but is not universal. Without coverage, the out-of-pocket cost can range from a few hundred to over a thousand dollars, depending on the panel.

How Does NIPT Compare to Other Prenatal Tests?

NIPT is one of several prenatal screening and diagnostic options. Each has different strengths and limitations.

• NIPT: Blood test. Screens for trisomy 21, 18, and 13. High accuracy for these conditions. No miscarriage risk. Does not screen for neural tube defects.
• First-trimester combined screening: Ultrasound and blood test. Screens for trisomies and neural tube defects. Usually done between 11 and 14 weeks. Lower detection rate for trisomy 21 than NIPT.
• Second-trimester maternal serum screening: Blood test. Screens for trisomies and neural tube defects. Usually done between 15 and 22 weeks.
• Amniocentesis: Diagnostic test. Samples amniotic fluid. Can diagnose chromosomal conditions with high certainty. Small miscarriage risk.
• Chorionic villus sampling: Diagnostic test. Samples placental tissue. Can diagnose chromosomal conditions earlier than amniocentesis. Small miscarriage risk.

Some people have both NIPT and a maternal serum screening test. This can provide information about neural tube defects that NIPT does not cover. The choice depends on what information you want and what your clinician recommends.

What Are the Limitations of NIPT?

NIPT is a screening test. It cannot diagnose a condition. A positive result requires confirmation. A negative result does not rule out all genetic conditions.

NIPT does not detect structural birth defects like heart defects or neural tube defects. It does not detect most single-gene disorders. It does not detect conditions that arise after birth.

The test can fail to produce a result. This happens in a small percentage of cases, often due to low fetal fraction. When this occurs, the test may be repeated, or another screening method may be used.

NIPT results can be affected by factors that have nothing to do with the fetus. A pregnant person with cancer, for example, can have abnormal cell-free DNA that leads to an unexpected result. This is rare but documented. It is one reason results are interpreted by clinicians who understand the full context.